As we all know, although endocrine therapy is effective to decrease the risk of recurrence for ER+ breast cancer patients, this therapies bring inevitable adverse events, e.g. increasing risk of developing endometrial cancer. To bring the personalized strategy for this group of patients a step forward, could we avoid prescribing endocrine therapy for a group early stage patients without increasing the risk of recurrence and contralateral cancer?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.